pantoprazole has been researched along with Overweight in 2 studies
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.
Overweight: A status with BODY WEIGHT that is above certain standards. In the scale of BODY MASS INDEX, overweight is defined as having a BMI of 25.0-29.9 kg/m2. Overweight may or may not be due to increases in body fat (ADIPOSE TISSUE), hence overweight does not equal over fat.
Excerpt | Relevance | Reference |
---|---|---|
"A total of 200 overweight or obese patients with RE-AB were evenly randomized into a double-dosed group (receiving 8-week pantoprazole 40 mg twice daily) or a standard-dosed control group (receiving 8-week pantoprazole 40 mg per day and one blank tablet at night)." | 9.14 | Double-dosed pantoprazole accelerates the sustained symptomatic response in overweight and obese patients with reflux esophagitis in Los Angeles grades A and B. ( Chang, WL; Chen, WY; Cheng, HC; Lu, CC; Sheu, BS; Tsai, YC, 2010) |
"Overweight/obesity in GORD patients does not appear to affect the antisecretory efficacy of a single dose of rabeprazole and pantoprazole." | 5.17 | On-demand proton pump inhibitory treatment in overweight/obese patients with gastroesophageal reflux disease: are there pharmacodynamic arguments for using higher doses? ( Bruley des Varannes, S; Coudsy, B; Delemos, B; Ducrotté, P; Lococo, J; Waechter, S; Xiang, J, 2013) |
"A total of 200 overweight or obese patients with RE-AB were evenly randomized into a double-dosed group (receiving 8-week pantoprazole 40 mg twice daily) or a standard-dosed control group (receiving 8-week pantoprazole 40 mg per day and one blank tablet at night)." | 5.14 | Double-dosed pantoprazole accelerates the sustained symptomatic response in overweight and obese patients with reflux esophagitis in Los Angeles grades A and B. ( Chang, WL; Chen, WY; Cheng, HC; Lu, CC; Sheu, BS; Tsai, YC, 2010) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bruley des Varannes, S | 1 |
Coudsy, B | 1 |
Waechter, S | 1 |
Delemos, B | 1 |
Xiang, J | 1 |
Lococo, J | 1 |
Ducrotté, P | 1 |
Chen, WY | 1 |
Chang, WL | 1 |
Tsai, YC | 1 |
Cheng, HC | 1 |
Lu, CC | 1 |
Sheu, BS | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Comparing Dexlansoprazole With Double-dose Lansoprazole to Achieve Sustained Symptomatic Response in Overweight and Obesity Patients With Reflux Esophagitis in Los Angeles Grades A & B[NCT02759393] | Phase 4 | 200 participants (Anticipated) | Interventional | 2015-10-31 | Enrolling by invitation | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
2 trials available for pantoprazole and Overweight
Article | Year |
---|---|
On-demand proton pump inhibitory treatment in overweight/obese patients with gastroesophageal reflux disease: are there pharmacodynamic arguments for using higher doses?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Cross-Over Studies; Double-Blind M | 2013 |
Double-dosed pantoprazole accelerates the sustained symptomatic response in overweight and obese patients with reflux esophagitis in Los Angeles grades A and B.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Body Mass Index; Dose-Response Relationship, D | 2010 |